tiprankstipranks
BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Press Releases

BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks –

– Announced appointment of commercial strategy and operations veteran Holly May as U.S.-based Chief Commercial Officer –

– Entered into collaboration agreement with GenFleet Therapeutics to advance Motixafortide in pancreatic cancer (PDAC) –

– Management to hold conference call today, August 16, at 10:00 am EDT –

TEL AVIV, Israel, Aug. 16, 2022 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reports its financial results for the second quarter ended June 30, 2022 and provides a corporate update.

Significant events and achievements during the second quarter 2022 and subsequent period:

  • Progressed the New Drug Application (NDA) for Motixafortide in stem cell mobilization (SCM), with submission to the FDA expected within the next 4-6 weeks;
  • Appointed commercial strategy and operations veteran Holly May as Chief Commercial Officer, based in the U.S.;
  • Continued to advance critical pre-launch activities with respect to Motixafortide commercialization in the U.S., if approved;
  • Entered into a development collaboration agreement with GenFleet Therapeutics to execute a randomized Phase 2b clinical trial of Motixafortide, in combination with anti-PD1 and chemotherapy, for first-line treatment in approximately 200 pancreatic cancer (PDAC) patients in China;
  • Ended the second quarter on solid financial footing, with cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, into the first half of 2024.

“Since our last quarterly update, we achieved significant progress across both our Motixafortide stem cell mobilization and pancreatic cancer (PDAC) programs,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “With respect to stem cell mobilization, we are in the final stages of preparing for submission of our NDA to the FDA. With Holly May on board as our new Chief Commercial Officer, we are rapidly advancing critical pre-launch activities while we continue to assess all of our options with respect to commercialization of Motixafortide in the U.S., if approved.”

“The totality of data that we have compiled in stem cell mobilization, both clinical and pharmacoeconomic, make an extremely strong case for Motixafortide as the standard of care in this indication for all multiple myeloma patients undergoing autologous stem-cell transplantation, which is a highly concentrated end market estimated to be $360 million in the U.S. alone and growing consistently.”

“In PDAC, the development collaboration agreement that we announced with GenFleet builds upon the positive results from our COMBAT/KEYNOTE-202 study, and we look forward to the initiation of a randomized Phase 2b PDAC trial next year. Importantly, this collaboration allows us to advance the development of Motixafortide in PDAC while retaining rights to the molecule across all indications and geographies.”

“Finally, we are nearing a significant milestone for our second program, the anti-cancer vaccine AGI-134, with the upcoming release of proof-of-mechanism data from part 2 of a Phase 1/2a trial in solid tumors. If positive, we plan to initiate a randomized Phase 2 study next year.”

“In summary, we believe we are well-positioned to deliver several meaningful potential regulatory, commercial and clinical catalysts over the next 12-18 months,” concluded Mr. Serlin.

Upcoming Expected Milestones:

  • Submission of NDA to FDA for Motixafortide as novel mobilization agent for multiple myeloma patients undergoing autologous stem cell transplantation in next 4-6 weeks;
  • Initial results from Part 2 of Phase 1/2a trial of AGI-134 in solid tumors in H2 2022;
  • Potential FDA approval of Motixafortide in 2023;
  • Potential US launch of Motixafortide in SCM in 2023;
  • Initiation of randomized Phase 2b study in PDAC under collaboration with GenFleet in 2023;
  • Potential initiation of randomized Phase 2 study of AGI-134 in 2023.

Financial Results for the Quarter Ended June 30, 2022: 

Research and development expenses for the three months ended June 30, 2022 were $5.4 million, an increase of $0.3 million, or 5.0%, compared to $5.1 million for the three months ended June 30, 2021. The increase resulted primarily from an increase in expenses associated with the AGI-134 study, offset by lower expenses associated with the completed Motixafortide GENESIS trial, as well as lower expenses related to NDA supporting activities related to Motixafortide. Research and development expenses for the six months ended June 30, 2022 were $9.8 million, an increase of $0.4 million, or 4.4%, compared to $9.4 million for the six months ended June 30, 2021. The reason for the increase is similar to the aforementioned increase in the three-month period.

Sales and marketing expenses for the three months ended June 30, 2022 were $1.2 million, an increase of $0.8 million, or 250.9% compared to $0.3 million for the three months ended June 30, 2021. The increase resulted primarily from initiation of pre-commercialization activities related to Motixafortide, as well as an increase in market research. Sales and marketing expenses for the six months ended June 30, 2022 were $1.8 million, an increase of $1.3 million, or 270.9% compared to $0.5 million for the six months ended June 30, 2021. The reason for the increase is similar to the aforementioned increase in the three-month period.

General and administrative expenses for the three months ended June 30, 2022 were $1.0 million, similar to the comparable period in 2021. General and administrative expenses for the six months ended June 30, 2022 were $2.1 million, similar to the comparable period in 2021.

The Company’s operating loss for the three months ended June 30, 2022 amounted to $7.6 million, compared to an operating loss of $6.5 million for the comparable period in 2021. The Company’s operating loss for the six months ended June 30, 2022 was $13.7 million, compared to $12.0 million for the comparable period in 2021.

Non-operating income (expenses) for the three and six months ended June 30, 2022 and for the three and six months ended June 30, 2021 primarily relate to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering expenses.

Net financial expenses for the three months ended June 30, 2022 amounted to $0.3 million, compared to net financial expenses of $0.1 million for the three months ended June 30, 2021. Net financial expenses for the 2022 period primarily relate to loan interest paid and losses recorded on foreign currency (primarily NIS) cash balances due to the strengthening of the US dollar during the period, offset by investment income earned on bank deposits. Net financial expenses for the 2021 period primarily relate to loan interest paid, offset by investment income earned on bank deposits. Net financial expenses for the six months ended June 30, 2022 amounted to $0.4 million, compared to net financial expenses of $0.3 million for the six months ended June 30, 2021. The composition of the expenses is similar to the aforementioned composition detailed in the three-month periods.

The Company’s net loss for the three months ended June 30, 2022 amounted to $7.4 million, compared with a net loss of $6.8 million for the comparable period in 2021. The Company’s net loss for the six months ended June 30, 2022 amounted to $12.4 million, compared with a net loss of $17.0 million for the comparable period in 2021.

The Company held $43.2 million in cash, cash equivalents and short-term bank deposits as of June 30, 2022.

Net cash used in operating activities was $11.9 million for the six months ended June 30, 2022, compared with net cash used in operating activities of $13.1 million for the six months ended June 30, 2021. The $1.2 million decrease in net cash used in operating activities between the two periods was primarily the result of changes in operating asset and liability items in the two periods, i.e., a smaller increase in prepaid expenses and other receivables in 2022 versus 2021, as well as an increase in accounts payable and accruals in 2022 versus decrease in the 2021 period.

Net cash provided by investing activities was $15.1 million for the six months ended June 30, 2022, compared to net cash used in investing activities of $42.3 million for the six months ended June 30, 2021. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits.

Net cash used in financing activities was $1.6 million for the six months ended June 30, 2022, compared to net cash provided by financing activities of $56.0 million for the six months ended June 30, 2021. The cash flows in 2022 primarily reflect the repayments of the loan from Kreos Capital. The cash flows in 2021 primarily reflect the underwritten public offering of the Company’s ADSs in January 2021, warrant exercises and net proceeds from the ATM facility, offset by repayments of the loan from Kreos Capital.

Conference Call and Webcast Information

BioLineRx will hold a conference call today, Tuesday, August 16 at 10:00 a.m. EDT. To access the conference call, please dial +1-888-281-1167 from the US or +972-3-918-0685 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until August 18, 2022; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

(Tables follow)

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company’s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, has successfully completed a pre-NDA meeting with the FDA, and is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy, and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy.

BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events.

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” and “would,” and describe opinions about future events. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx’s preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx’s therapeutic candidates; BioLineRx’s ability to establish and maintain corporate collaborations; BioLineRx’s ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx’s therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx’s business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx’s industry; statements as to the impact of the political and security situation in Israel on BioLineRx’s business; and the impact of the COVID-19 pandemic and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 16, 2022. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthy

LifeSci Advisors, LLC

+1-917-679-9282

tim@lifesciadvisors.com

or

Moran Meir

LifeSci Advisors, LLC

+972-54-476-4945

moran@lifesciadvisors.com

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)


December 31,

June 30,


2021

2022


in USD thousands

Assets



CURRENT ASSETS



Cash and cash equivalents

12,990

14,000

Short-term bank deposits

44,145

29,146

Prepaid expenses

127

717

Other receivables

142

240

          Total current assets

57,404

44,103




NON-CURRENT ASSETS



Property and equipment, net

952

810

Right-of-use assets, net

1,331

1,221

Intangible assets, net

21,704

21,704

          Total non-current assets

23,987

23,735

          Total assets

81,391

67,838




Liabilities and equity



CURRENT LIABILITIES



Current maturities of long-term loan

2,757

1,013

Accounts payable and accruals:



     Trade

5,567

7,338

     Other

1,227

1,132

Current maturities of lease liabilities

168

149

          Total current liabilities

9,719

9,632

NON-CURRENT LIABILITIES



Warrants

1,859

186

Lease liabilities

1,726

1,452

          Total non-current liabilities

3,585

1,638

COMMITMENTS AND CONTINGENT LIABILITIES



     Total liabilities

13,304

11,270




EQUITY



Ordinary shares

21,066

21,157

Share premium

339,346

339,670

Warrants

975

975

Capital reserve

13,157

13,596

Other comprehensive loss

(1,416)

(1,416)

Accumulated deficit

(305,041)

(317,414)

          Total equity

68,087

56,568

          Total liabilities and equity

81,391

67,838

 

 

 

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)


Three months ended June 30,

Six months ended June 30,


2021

2022

2021

2022


in USD thousands

in USD thousands

RESEARCH AND DEVELOPMENT EXPENSES

(5,139)

(5,395)

(9,417)

(9,830)

SALES AND MARKETING EXPENSES

(330)

(1,158)

(484)

(1,795)

GENERAL AND ADMINISTRATIVE EXPENSES

(1,044)

(1,049)

(2,061)

(2,056)

OPERATING LOSS

(6,513)

(7,602)

(11,962)

(13,681)

NON-OPERATING INCOME (EXPENSES), NET

(217)

458

(4,778)

1,726

FINANCIAL INCOME

130

80

247

147

FINANCIAL EXPENSES

(242)

(379)

(541)

(565)

NET LOSS AND COMPREHENSIVE LOSS

(6,842)

(7,443)

(17,034)

(12,373)







in USD

in USD

LOSS PER ORDINARY SHARE – BASIC AND DILUTED

(0.01)

(0.01)

(0.03)

(0.02)






WEIGHTED AVERAGE NUMBER OF SHARES USED IN

CALCULATION OF LOSS PER ORDINARY SHARE

669,138,994

715,365,554

614,780,845

715,260,781

 

 

 

BioLineRx Ltd.

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED) 


 

Ordinary

Share


Capital

Other

comprehensive

Accumulated



shares

premium

Warrants

reserve

loss

deficit

Total


in USD thousands

BALANCE AT JANUARY 1, 2021

9,870

279,241

12,322

(1,416)

(277,987)

22,030

CHANGES FOR SIX MONTHS ENDED

JUNE 30, 2021:








Issuance of share capital, net

8,386

37,495

975

46,856

Warrants exercised

2,235

18,967

21,202

Employee stock options exercised

5

41

(39)

7

Employee stock options forfeited and expired

143

(143)

Share-based compensation     

832

832

Comprehensive loss for the period

(17,034)

(17,034)

BALANCE AT JUNE 30, 2021

20,496

335,887

975

12,972

(1,416)

(295,021)

73,893










 

Ordinary

 

Share


 

Capital

Other

comprehensive

 

Accumulated



shares

premium

Warrants

reserve

loss

deficit

Total


in USD thousands

BALANCE AT JANUARY 1, 2022

21,066

339,346

975

13,157

(1,416)

(305,041)

68,087

CHANGES FOR SIX MONTHS ENDED

JUNE 30, 2022:








Issuance of share capital, net

89

177

266

Employee stock options exercised

2

12

(12)

2

Employee stock options forfeited and expired

135

(135)

Share-based compensation     

586

586

Comprehensive loss for the period

(12,373)

(12,373)

BALANCE AT JUNE 30, 2022

21,157

339,670

975

13,596

(1,416)

(317,414)

56,568









 

 

 

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)


 

Ordinary

 

Share


 

Capital

Other

comprehensive

 

Accumulated



shares

premium

Warrants

reserve

loss

deficit

Total


in USD thousands

BALANCE AT APRIL 1, 2021

18,731

321,920

975

12,616

(1,416)

(288,179)

64,647

CHANGES FOR THREE MONTHS ENDED JUNE 30, 2021:








Issuance of share capital, net

1,581

12,516

14,097

Warrants exercised

184

1,444

1,628

Employee stock options exercised

3

(1)

2

Employee stock options forfeited and expired

4

(4)

Share-based compensation     

361

361

Comprehensive loss for the period

(6,842)

(6,842)

BALANCE AT JUNE 30, 2021

20,496

335,887

975

12,972

(1,416)

(295,021)

73,893










 

Ordinary

 

Share


 

Capital

Other

comprehensive

 

Accumulated



shares

premium

Warrants

reserve

loss

deficit

Total


in USD thousands

BALANCE AT APRIL 1, 2022

21,066

339,444

975

13,315

(1,416)

(309,971)

63,413

CHANGES FOR THREE MONTHS ENDED

     JUNE 30, 2022:








Issuance of share capital, net

89

177

266

Employee stock options exercised

2

12

(12)

2

Employee stock options forfeited and expired

37

(37)

Share-based compensation     

330

330

Comprehensive loss for the period

(7,443)

(7,443)

BALANCE AT JUNE 30, 2022

21,157

339,670

975

13,596

(1,416)

(317,414)

56,568









 

 

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)


Six months ended June 30,


2021

2022


in USD thousands




CASH FLOWS – OPERATING ACTIVITIES



Net loss for the period

(17,034)

(12,373)

Adjustments required to reflect net cash used in operating activities

(see appendix below)

3,977

498

Net cash used in operating activities

(13,057)

(11,875)




CASH FLOWS – INVESTING ACTIVITIES



Investments in short-term deposits

(58,000)

(9,000)

Maturities of short-term deposits

15,776

24,141

Purchase of property and equipment

(38)

(62)

Net cash provided by (used in) investing activities

(42,262)

15,079




CASH FLOWS – FINANCING ACTIVITIES



Issuance of share capital and warrants, net of issuance costs

46,856

266

Exercise of warrants

10,907

Employee stock options exercised

7

2

Repayments of loan

(1,648)

(1,812)

Repayments of lease liabilities

(122)

(88)

Net cash provided by (used in) financing activities

56,000

(1,632)




INCREASE IN CASH AND CASH EQUIVALENTS

681

1,572

CASH AND CASH EQUIVALENTS – BEGINNING

   OF PERIOD

16,831

12,990

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

(28)

(562)

CASH AND CASH EQUIVALENTS – END OF PERIOD

17,484

14,000




 

BioLineRx Ltd.

APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)


Six months ended June 30,


2021

2022


in USD thousands







Adjustments required to reflect net cash used in operating activities:



Income and expenses not involving cash flows:



Depreciation and amortization

362

314

Exchange differences on cash and cash equivalents

28

562

Fair value adjustments of warrants

4,889

(1,673)

Share-based compensation

832

586

Interest and exchange differences on short-term deposits

(103)

(142)

Interest on loan

176

68

Exchange differences on lease liability 

(26)

(205)


6,158

(490)




Changes in operating asset and liability items:



Increase in prepaid expenses and other receivables

(1,212)

(688)

Increase (decrease) in accounts payable and accruals

(969)

1,676


(2,181)

988


3,977

498







Supplemental information on interest received in cash

39

146




Supplemental information on interest paid in cash

350

217




Supplemental information on non-cash transactions:



Acquisition of right-of-use asset

171




Exercise of warrants (portion related to accumulated

fair value adjustments)

10,295




 

Cision View original content:https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2022-financial-results-and-provides-corporate-update-301606394.html

SOURCE BioLineRx Ltd.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles